MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Jan. 6, 2006--Perlegen Sciences, Inc. announced today that it has begun a collaboration with Genentech, Inc. (NYSE:DNA) to study the genetics of cancer. Findings from the study could potentially be applied to the discovery and development of targeted medicines and molecular diagnostics for the disease. Perlegen’s high throughput oligonucleotide array approach utilizes Affymetrix (Nasdaq:AFFX) GeneChip(R) technology. Cancer is the second leading cause of death in the United States. It has been estimated that approximately one-half of all men and one-third of all women will develop some form of cancer during their lifetimes. An improved understanding of the genetics of cancer may enable the development of novel therapeutics and diagnostic tests for cancer, as well as better targeting of cancer treatments to responsive patient populations.
